Four analysts set EUR 51.00 target for Dermapharm stock

Four analysts put Dermapharm Holding SE (ISIN DE000A2GS5D8) on a EUR 51.00 12-month consensus target, according to Investing.com on October 16, 2026. The target stood 34.74 percent above Dermapharm's EUR 37.85 closing price from October 16, 2026.

Target gap shapes the setup

The consensus covered four analysts and showed a target range from EUR 44.00 to EUR 60.00. Dermapharm's average target therefore sat EUR 13.15 above the closing price, giving investors a clear valuation reference without turning it into a recommendation.

Stock stays in a wide range

The stock's 52-week range extended from EUR 32.40 to EUR 51.90 on October 16, 2026. The closing price was EUR 14.05 below the high, a distance of 27.07 percent, while it stood EUR 5.45 above the low. The October 16 session covered EUR 37.65 to EUR 38.70 and ended with 14,600 shares traded.

Valuation and company profile

Dermapharm had a market capitalization of EUR 1.9 billion and a P/E ratio of 13.66 as of October 16, 2026. The specialty pharmaceutical group develops, manufactures and sells branded generic medicines, over-the-counter products and healthcare items, with activities spanning branded pharmaceuticals, parallel imports and herbal extracts.

Comparison with peers

Dermapharm: minus 0.79 percent, P/E 13.66, market capitalization EUR 1.9 billion
Fresenius (Xetra, EUR): plus 2.78 percent, P/E 16.39, market capitalization EUR 25.4 billion
Bayer (Xetra, EUR): plus 0.11 percent, P/E minus 25.26, market capitalization EUR 43.7 billion

Price and investor perspective

Dermapharm's position between its 52-week low and high leaves the EUR 51.00 consensus target as the clearest external valuation marker. The next market session will show whether the stock can hold above the October 16 closing level.

The closing price of Dermapharm stock was EUR 37.85 on Xetra on October 16, 2026.